Compare Invesco Ltd. (IVZ) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs Philip Morris International Inc. — how do they compare? Invesco Ltd. trades at $30.09 (market cap $13.28B), while Philip Morris International Inc. trades at $199.8 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 23.5× Invesco Ltd.'s market cap, and Philip Morris International Inc. pays the higher dividend (3.19%). Which is the better fit depends on your goals — on Pluang, investors hold Invesco Ltd. for 77 Days and Philip Morris International Inc. for 85 Days on average.
| IVZ | PM | |
|---|---|---|
Market Cap | $13.28B | $312.50B |
Volume | 3,698,033 | 5,517,172 |
Sector | Financials | Consumer Staples |
52-Week High | $33.31 | $200.50 |
52-Week Low | $22.44 | $144.33 |
Typical Hold Time | 77 Days | 85 Days |
Enterprise Value | $23.45B | $355.62B |
Dividend Yield | 2.86% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Invesco (IVZ) trades at $30.50, showing modest daily gains of 0.39%. The stock presents mixed signals with bearish technical indicators but positive analyst sentiment featuring 12 buy ratings and a $33.71 consensus target. Recent financials show revenue growth to $6.38B in 2025, though net income remains negative at -$281.70M. The company maintains strong operating cash flow of $1.53B and recently announced a $0.22 dividend for H2-2026.
Investment outlook balances analyst optimism against fundamental challenges. The 8.8% upside to consensus target suggests potential, but negative profitability metrics and bearish technicals warrant caution. Key catalysts include Q3 2026 earnings release on October 27 and continued AUM growth momentum, while risks center on margin pressure and market volatility affecting asset management revenues.
Philip Morris International (PM) trades at $192.69, up 1.2% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 EPS beat expectations at $2.20 vs. $2.05, and revenue growth accelerated to $40.65B in 2025. The company's smoke-free products now drive 42% of revenue, with ZYN and IQOS expansions fueling optimism. Cash flow remains robust, with 2026 operating cash flow projected at $14.3B, supporting dividend growth.
Outlook is positive given earnings momentum and smoke-free transition, but high debt ($42.17B long-term) and regulatory risks persist. The consensus price target of $212.17 implies ~10% upside, though valuation multiples are elevated versus peers. Key risks include FX volatility and slower adoption of next-gen products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
